Summary
In-vitro Fertilization (IVF) is a well-known fertility treatment used for infertile couples, single mothers and women in same-sex relationships. Of the nearly a million IVF cycles done in Europe annually (3 million globally), only 40% result in pregnancy. Low IVF success makes the process long, expensive, and emotionally devastating. Moreover, the dissimilar access to fertility treatments contributes to health inequity and gender imbalance, as infertility is still a women's social burden.
One of the leading causes of IVF failure is embryo transfer (ET), with live birth rates (ET-LBR) below 30% and lower than 10% in women around 40 years old. The main factors affecting ET-LBR are embryo quality, uterine receptivity, and embryo-uterine synchrony. Nowadays, the selection of high-quality embryos is solved; but in the presence of high-quality embryos the uterus determines the success of embryo implantation. However, assessing the uterine readiness for embryo transfer is done by counting days.
Therefore, an urgent unmet clinical need is to provide accuracy in detecting uterine receptivity and embryo-uterine synchrony to improve embryo implantation rates and IVF success.
We have created Seedchrony, a point-of-care device that detects endometrial receptivity non-invasively, and instantly, enabling right-on-time embryo transfer to boost IVF success. Unlike the standard of care (counting days) and the current solutions (tissue analysis requiring tissue biopsies and time for sample processing), Seedchrony is accurate, the measurements are done directly in the uterine fluid, and the results are immediate, allowing doing test and transfer on the same day.
Manina Medtech is a pre-seed stage startup with a B2B business model and the vision that every woman who goes through IVF requires a single IVF cycle to get pregnant. We position to fundamentally boost IVF success, making the whole process faster, healthier, and more affordable.
One of the leading causes of IVF failure is embryo transfer (ET), with live birth rates (ET-LBR) below 30% and lower than 10% in women around 40 years old. The main factors affecting ET-LBR are embryo quality, uterine receptivity, and embryo-uterine synchrony. Nowadays, the selection of high-quality embryos is solved; but in the presence of high-quality embryos the uterus determines the success of embryo implantation. However, assessing the uterine readiness for embryo transfer is done by counting days.
Therefore, an urgent unmet clinical need is to provide accuracy in detecting uterine receptivity and embryo-uterine synchrony to improve embryo implantation rates and IVF success.
We have created Seedchrony, a point-of-care device that detects endometrial receptivity non-invasively, and instantly, enabling right-on-time embryo transfer to boost IVF success. Unlike the standard of care (counting days) and the current solutions (tissue analysis requiring tissue biopsies and time for sample processing), Seedchrony is accurate, the measurements are done directly in the uterine fluid, and the results are immediate, allowing doing test and transfer on the same day.
Manina Medtech is a pre-seed stage startup with a B2B business model and the vision that every woman who goes through IVF requires a single IVF cycle to get pregnant. We position to fundamentally boost IVF success, making the whole process faster, healthier, and more affordable.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101114020 |
| Start date: | 01-06-2023 |
| End date: | 29-02-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
In-vitro Fertilization (IVF) is a well-known fertility treatment used for infertile couples, single mothers and women in same-sex relationships. Of the nearly a million IVF cycles done in Europe annually (3 million globally), only 40% result in pregnancy. Low IVF success makes the process long, expensive, and emotionally devastating. Moreover, the dissimilar access to fertility treatments contributes to health inequity and gender imbalance, as infertility is still a women's social burden.One of the leading causes of IVF failure is embryo transfer (ET), with live birth rates (ET-LBR) below 30% and lower than 10% in women around 40 years old. The main factors affecting ET-LBR are embryo quality, uterine receptivity, and embryo-uterine synchrony. Nowadays, the selection of high-quality embryos is solved; but in the presence of high-quality embryos the uterus determines the success of embryo implantation. However, assessing the uterine readiness for embryo transfer is done by counting days.
Therefore, an urgent unmet clinical need is to provide accuracy in detecting uterine receptivity and embryo-uterine synchrony to improve embryo implantation rates and IVF success.
We have created Seedchrony, a point-of-care device that detects endometrial receptivity non-invasively, and instantly, enabling right-on-time embryo transfer to boost IVF success. Unlike the standard of care (counting days) and the current solutions (tissue analysis requiring tissue biopsies and time for sample processing), Seedchrony is accurate, the measurements are done directly in the uterine fluid, and the results are immediate, allowing doing test and transfer on the same day.
Manina Medtech is a pre-seed stage startup with a B2B business model and the vision that every woman who goes through IVF requires a single IVF cycle to get pregnant. We position to fundamentally boost IVF success, making the whole process faster, healthier, and more affordable.
Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
